Glenmark Pharma reported a sharply higher Q2 profit driven by an exceptional gain, while underlying performance across North America, Europe and emerging markets remained steady. India sales were temporarily impacted by GST-related adjustments.
Glenmark Pharma reported a sharply higher Q2 profit driven by an exceptional gain, while underlying performance across North America, Europe and emerging markets remained steady. India sales were temporarily impacted by GST-related adjustments.
